Improved cysteine-producing strains
Patent Information
- Application Number
- EP2022712547
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2022-03-01
- Publication Date
- 2024-11-20
AI Technical Summary
Current microorganism strains used for fermentative production of cysteine, L-cystine, and thiazolidine have regulated cysteine biosynthesis pathways, limiting production yields due to feedback inhibition and low solubility of cystine, which complicates purification and reduces economic efficiency.
A microorganism strain with a deregulated cysteine biosynthesis pathway, achieved by reducing the relative expression of the crp gene through mutation of the crp promoter sequence, enhancing the production of L-cysteine, L-cystine, and thiazolidine by altering the crp promoter sequence without changing the Crp protein amino acid sequence.
This approach results in significantly higher yields of cysteine, cystine, and thiazolidine, improving the economic efficiency of the fermentation process by reducing feedback inhibition and facilitating easier product recovery.
Smart Images

Figure 1.1
Abstract
Description
[0001] Improved cysteine-producing strains
[0002] The invention relates to a microorganism strain comprising a deregulated cysteine biosynthesis pathway, which is thereby suitable for the fermentative production of at least one substance selected from L-cysteine, L-cystine, and thiazolidine, characterized in that the relative expression of the crp gene is reduced by mutation of the crp promoter sequence relative to the expression of the crp gene with wild-type promoter sequence. A particular advantage is that this microorganism strain produces an increased amount of a substance selected from L-cysteine, L-cystine, and thiazolidine compared to the corresponding microorganism strain expressing the crp gene with a wild-type promoter. The invention therefore also provides a process for producing at least one compound selected from L-cysteine and its derivatives L-cystine and thiazolidine using this microorganism strain.
[0003] Cysteine, abbreviated Cys or C, is an α-amino acid with the side chain -CH2-SH. Since the naturally occurring enantiomeric form is L-cysteine and this is the only proteinogenic amino acid, in the context of this invention L-cysteine is meant when the term cysteine is used without a descriptor. By oxidation of the sulfhydryl groups, two cysteine residues can form a disulfide bridge with each other, producing cystine, for which the same applies, i.e. without a descriptor in this invention the L-enantiomer (or L-cystine, or (R,R)-3,3'-dithio-bis (2-aminopropionic acid)) is meant. L-cysteine is a semi-essential amino acid for humans, as it can be formed from the amino acid methionine. Thiazolidine refers to the compound 2-methyl-2,4-thiazolidinedicarboxylic acid, an adduct of cysteine and pyruvate (EP 0885 962 Bl).
[0004] Cysteine plays a key role in sulfur metabolism in all organisms and is used in the synthesis of proteins, glutathione, biotin, lipoic acid, thiamine, taurine, methionine, and other sulfur-containing metabolites. L-cysteine also serves as a precursor for the biosynthesis of coenzyme A.
[0005] Cysteine biosynthesis has been studied in detail in bacteria, particularly in enterobacteria. A summary of cysteine biosynthesis can be found in Wada and Takagi, Appl. Microbiol. Biotechnol. (2006) 73: 48-54.
[0006] The amino acid L-cysteine is of commercial importance. It is used, for example, as a food additive (particularly in the baking industry), as an ingredient in cosmetics, and as a starting material for the production of pharmaceutical active ingredients (particularly N-acetylcysteine and S-carboxymethylcysteine).
[0007] In addition to the traditional method of obtaining cysteine by extraction from keratin-containing material such as hair, bristles, horns, hooves, and feathers, or by biotransformation through enzymatic conversion of precursors, a process for the fermentative production of cysteine is also available. The state of the art regarding the fermentative production of cysteine using microorganisms is disclosed, for example, in EP 0858 510 B1, EP 0885 962 B1, EP 1382 684 B1, EP 1220 940 B2, EP 1769 080 B1, EP 2138585 B1, and WO 2021 / 259491. Strains of the genus Corynebacterium and members of the Enterobacteriaceae family, such as Escherichia coli or Pantoea ananatis, are used as bacterial host organisms.
[0008] Wild-type host organisms that have not been further modified do contain a cysteine biosynthesis pathway (see, for example, the KEGG Pathway Database: “Cysteine and methionine metabolism”), but this pathway is regulated in such a way that only as much cysteine is produced as is required for cell growth. As described, for example, in a review article by Wada and Takagi 2006 (see above), in WT strains cysteine biosynthesis is regulated by so-called feedback inhibition of key enzymes. For example, L-serine inhibits the SerA enzyme 3-phosphoglycerate dehydrogenase, and L-cysteine inhibits the CysE enzyme serine-O-acetyltransferase. SerA and CysE are both enzymes of the cysteine biosynthesis pathway, and their feedback inhibition by L-serine or L-cysteine prevents more cysteine from being produced than required by the cell. Such wild-type strains do not produce detectable cysteine, as shown in Table 2 of the present invention for strain E.coli K12 W3110 and are therefore not suitable for cysteine production despite the presence of a cysteine biosynthesis pathway. A wild-type microorganism strain becomes suitable for cysteine production by deregulating the cysteine biosynthesis pathway. Various methods are available for the production of microorganism strains with deregulated cysteine biosynthesis that are characterized by improved cysteine production. In addition to the classic approach of achieving improved cysteine producers through mutation and selection, targeted genetic modifications have also been made to the strains to achieve effective cysteine overproduction.
[0009] For example, the introduction of a cysE allele encoding a serine O-acetyltransferase with reduced feedback inhibition by cysteine led to an increase in cysteine production (EP 0 858 510 Bl; Nakamori et al., Appl. Env. Microbiol. (1998) 64: 1607-1611). A feedback-resistant CysE enzyme largely decouples the formation of O-acetyl-L-serine, the direct precursor of cysteine, from the cellular cysteine level.
[0010] O-Acetyl-L-serine is formed from L-serine and acetyl-CoA. Therefore, the provision of sufficient L-serine for cysteine production is of great importance. This can be achieved by introducing a serA allele, which encodes a 3-phosphoglycerate dehydrogenase with reduced feedback inhibition by L-serine. This largely decouples the formation of 3-phosphohydroxypyruvate, a biosynthetic precursor of L-serine, from the L-serine level in the cell. Examples of such SerA enzymes are described in EP 0 620 853 B1 and EP 1496 111 B1. See also Bell et al., Eur. J. Biochem. (2002) 269: 4176-4184 reveal changes in the serA gene to deregulate enzyme activity.
[0011] Increasing the transport of cysteine out of the cell is another way to increase product yield in the medium. This can be achieved by overexpressing so-called efflux genes. These genes encode membrane-bound proteins that mediate the export of cysteine from the cell. Various efflux genes for cysteine export have been described (EP 0885 962 B1, EP 1382 684 B1). The export of cysteine from the cell into the fermentation medium has several advantages:
[0012] 1) L-cysteine is continuously removed from the intracellular reaction equilibrium, with the result that the level of this amino acid in the cell is kept low and thus the feedback inhibition of sensitive enzymes by L-cysteine is prevented:
[0013] (1) L-cysteine (intracellular) <-> L-cysteine (medium)
[0014] 2) The L-cysteine excreted into the medium is oxidized to the disulfide L-cystine in the presence of oxygen, which is introduced into the medium during cultivation (EP 0 885 962 Bl):
[0015] (2) 2 L-cysteine + 1 / 2 O2 -> L-cystine + H2O
[0016] Since the solubility of L-cystine in aqueous solution at a neutral pH is very low compared to cysteine, the disulfide precipitates even at low concentrations and forms a white precipitate:
[0017] (3) L-cystine (dissolved) -> L-cystine (precipitate)
[0018] The precipitation of L-cystine lowers the level of the product dissolved in the medium, which also pulls the reaction equilibrium of (1) and (2) towards the product side.
[0019] 3) The technical effort for purifying the product is significantly lower if the amino acid can be obtained directly from the fermentation medium than if the product accumulates intracellularly and cell disruption must first take place.
[0020] A cysteine producing strain / microorganism strain capable of cysteine production / microorganism strain with deregulated cysteine biosynthesis pathway / microorganism strain with deregulated cysteine biosynthesis is characterized by at least one of the alterations / traits selected from feedback-resistant SerA enzyme, feedback-resistant CysE enzyme and overexpression of a cysteine efflux protein.
[0021] Furthermore, it is known that the cysteine yield in fermentation can be increased by attenuating or destroying genes encoding cysteine-degrading enzymes, such as the tryptophanase TnaA or the cystathionine ß-lyases MalY or MetC (EP 1571 223 Bl).
[0022] In addition to genetically modifying the cysteine production strain, optimizing the fermentation process—that is, the method of culturing the cells—also plays an important role in developing an efficient production process. Various cultivation parameters, such as the type and dosage of the carbon and energy source, the temperature, the oxygen supply (EP 2 707 492 B1), the pH value, and the composition of the culture medium, can influence the product yield and / or the product spectrum in the fermentative production of cysteine.
[0023] Due to continuously rising raw material and energy costs, there is a continuing need to increase the product yield in cysteine production in order to improve the economic efficiency of the process.
[0024] The object of the present invention is to provide a microorganism strain for the fermentative production of cysteine, L-cystine and / or thiazolidine, with which higher yields of L-cysteine, L-cystine and / or thiazolidine can be achieved in the fermentation compared to known strains from the prior art.
[0025] The object is achieved by a microorganism strain comprising a deregulated cysteine biosynthesis pathway, which is thereby suitable for the fermentative production of at least one substance selected from L-cysteine, L-cystine and thiazolidine, characterized in that the relative expression of the crp gene is reduced by mutation of the crp promoter sequence relative to the expression of the crp gene with wild-type promoter sequence.
[0026] Crp, encoded by the crp gene, abbreviated for cyclic AMP (cAMP) receptor protein (or "catabolite repressor protein"), also known as CAP (catabolite activator protein), is a central transcription factor that is primarily known for mediating so-called catabolite repression, i.e., regulating gene expression depending on the carbon (C) source. For example, in E. coli, glucose is the preferred C source, and the expression of genes for metabolizing alternative C sources is repressed as long as glucose is available. Crp is activated by the binding of the signaling molecule cAMP (cyclic AMP) (referred to as Crp-cAMP). As Crp-cAMP, it influences the expression of target genes, thereby regulating not only the utilization of carbon sources but also other cellular functions such as nitrogen fixation, biofilm formation, transport of the trace element iron, and osmotic balance. Hanamura and Aiba, Nucleic Acids Res.(1991) 19: 4413-4419 further report that CrpcAMP can repress its own expression (negative autoregulation).
[0027] From transcriptome analyses (e.g., Gosset et al., J. Bacteriol. (2004) 186: 3516-3524), it is known that the expression of a large number of genes (>400 genes) is influenced by Crp or Crp-cAMP. Furthermore, Crp is part of a complex regulatory network of global transcription factors that interact with each other (outlined in Fig. 1 of Frendorf et al., Comput. Structural Biotechnol. J. (2019) 17: 730-736) and influence the expression of their target genes depending on the metabolic status of the cell.
[0028] If the expression of the crp gene is changed, it is not possible to make a priori a statement about how an increased or decreased crp expression affects the cellular metabolism in general or a biosynthetic metabolic pathway such as that of L-cysteine, due to the large number of genes regulated by Crp-cAMP as well as the mutually influencing global transcription factors.
[0029] Frendorf et al. (2019) (see above) provide an overview of the numerous Crp protein mutants investigated to date. These exclusively involve changes in the Crp amino acid sequence caused by alterations in the Crp cds. EP 3 686214, EP 3 686215, and EP 3725 800 (each CJ Corp., Korea) also disclose mutants of the Crp amino acid sequence and their use for the production of L-amino acids, particularly L-threonine and L-tryptophan.
[0030] The prior art has not investigated the effect on metabolism, in particular on cysteine biosynthesis, of altered expression of the crp WT gene as a result of a mutation of the crp promoter in a microorganism strain with a deregulated cysteine biosynthesis pathway. The present invention differs from the prior art in that it is preferably not the amino acid sequence of Crp that is altered, but rather the nucleotide sequence of the crp promoter. This means that in the prior art, the amino acid sequence and thus the activity properties of the Crp protein as a transcription factor were altered. In contrast, in the present invention, the amino acid sequence and thus the activity properties of the Crp protein (wild-type Crp) preferably remain unchanged; however, by altering the crp promoter, expression, i.e., the amount of protein, is altered.Based on the state of the art, it was not possible to predict how this measure would affect cellular metabolism in general and, in particular, cysteine biosynthesis in a microorganism strain with a deregulated cysteine biosynthesis pathway. For example, Liu et al., J. Agric. Food Chem 2020, 68: 14928-14937, describe in Fig. 2 of the publication the E. coli strain BW25113-pLH03, which exhibited both increased crp gene expression and improved L-cysteine production compared to the JM109-pLH03 strain. Therefore, it was completely unexpected that the reduced expression of the crp gene disclosed in the present invention would lead to improved cysteine production in a microorganism strain with a deregulated cysteine biosynthesis pathway.
[0031] The mutation of the CRP promoter sequence leads to attenuated CRP expression, preferably by shortening the CRP promoter sequence or by a combination of insertion and shortening of the CRP promoter sequence, with the CRP-cds particularly preferably remaining unchanged. The attenuated CRP expression leads, in a previously unknown manner, to improved production of L-cysteine in a microorganism strain with a deregulated cysteine biosynthesis pathway. In a particularly preferred embodiment, the mutation of the CRP promoter sequence leads to no CRP protein being expressed at all.
[0032] Detection of crp gene expression:
[0033] In order to compare the expression of the CRP gene in different strains, a method for the quantitative detection of CRP gene expression is required. Generally, various known test methods are available for the quantitative detection of gene expression. - An immunological detection method is based on the binding of a specific antibody to the expressed CRP protein. The methods ELISA ("Enzyme-linked Immunosorbent Assay") and Western Blot, known to those skilled in the art, thus enable the quantitative determination of the expressed protein through a color reaction that occurs via the bound CRP-specific antibody. - Another method for the quantitative detection of gene expression is based on the determination of the gene-specific RNA of an expressed gene, such as CRP RNA, in the entire cellular RNA (total RNA). For the purposes of the invention, the gene whose expression is to be examined is referred to as the target gene (e.g.The methods known to those skilled in the art are Northern blot for the direct detection of gene-specific RNA and the preferred real-time PCR (RT-PCR), also known as qPCR (quantitative PCR) for the indirect detection of gene-specific RNA (e.g., the crp RNA).
[0034] An RT-PCR analysis can be carried out as follows: 1) The cells to be analyzed (e.g. E. coli cells from the
[0035] Cultivation (as described in Example 4) of the strains to be analyzed (Examples 3 and 5) is mixed after harvesting with an RNA-stabilizing reagent (e.g. RNA-Protect® "Bacteria Reagent" from Qiagen), the total RNA is extracted (e.g. with the RNeasy RNA extraction kit from Qiagen) and quantified (e.g. using the "Qubit™ RNA BR Assay Kit" from Thermo Fisher Scientific).
[0036] 2) The total RNA of the strains is used to produce complementary DNA (cDNA) by reverse transcription (e.g. using the QuantiNova™ Reverse Transcription Kit from Qiagen) and the cDNA is quantified (e.g. using the "Qubit™ dsDNA HS Assay Kit" from Thermo Fisher Scientific).
[0037] 3) The cDNA is then used in accordance with the state of the art in an RT-PCR reaction with primers specific for the target gene (crp) as well as gene-specific primers for a reference gene (e.g., the cysG gene). Reagent kits for setting up RT-PCR reactions (e.g., from Qiagen) as well as devices for conducting RT-PCR analyses, including software for evaluation, are commercially available. For the analysis of crp expression described in Example 5, an RT-PCR device from Qiagen was used (RotorGene Q 2plex RT-PCR device, operated with the RotorGene Q control and evaluation software from the same manufacturer), with which the relative expression of the crp gene in strains with an altered crp promoter was determined relative to the reference strain E. coli W3110 x pCys with WT crp promoter. Relative expression: Within the scope of the invention, relative gene expression, determined as 2 -ΔΔCT-value, defined as the expression of the crp gene in the microorganism strain according to the invention with a deregulated cysteine biosynthesis pathway in which the crp promoter sequence has been mutated (e.g. the cysteine production strains E. coli W3110-crp ::kan-sacB x pCys, E. coli W3110-crpP-del x pCys, E. coli W3110-crp-Preg x pCys, E. coli W3110-crp-Preg2 x pCys and E. coli W3110-crp-Preg3 x pCys described in Example 3) in relation to the expression of the crp gene in a corresponding comparison strain (e.g. in the strain E. coli W3110 x pCys with WT crp promoter). The RT-PCR analysis method used in Example 5 of the present invention is based on the analysis of relative gene expression using quantitative RT-PCR and the so-called 2 -ΔΔCT Method. This analysis method is based on the RotorGene Q control and analysis software of the RotorGene Q 2plex RT-PCR instrument from Qiagen.
[0038] CT value: The basis for determining the relative gene expression is the so-called CT value (CT: "Cycle Threshold"), which is determined in the RT-PCR of the cDNA of a strain for both the crp gene (CT crp ) as determined for a reference gene. The reference gene serves to normalize the RT-PCR and is selected from known, constitutively expressed genes that are not subject to regulation. Within the scope of the invention, the CT value for the cysG gene (CT cysG ) was used as a reference gene, the expression of which is known to change little during cultivation (Zhou et al., BMC Molecular Biology (2011) 12:18).
[0039] ACT value: The ACT value is defined in the context of the invention as the difference between the CT values for the crp gene and the reference gene (e.g. cysG reference gene) of a strain.
[0040] ACT CT crp CT cycG .
[0041] AÄCT value: The AACT is defined in the context of the invention as the difference between the ACT value of a strain with altered expression of the crp gene and the ACT value of the reference strain with WT expression of the target gene (e.g., E. coli W3110 x pCys). AACT = ACT - ACT W3110 x pCys . 2 -ΔΔCT -Value: The value 2 AACT is formed from the AACT value, which is a measure of the expression of the crp gene in a modified strain compared to the expression of the crp gene in the comparison strain (e.g. E. coli W3110 x pCys) and is also referred to as relative expression of the target gene.
[0042] 4) Should the expression of the crp gene differ between different
[0043] strains, equal amounts of cDNA are used in RT-PCR and the relative crp expression is calculated as 2 -ΔΔCT -value is determined for each strain.
[0044] The 2 -ΔΔCT -value for the comparison master has the
[0045] Value 1. 2 -ΔΔCTValues > 1 indicate increased expression compared to the reference strain. 2 -ΔΔCT Values < 1 indicate a weakened expression compared to the reference strain.
[0046] From the comparison of the 2 -ΔΔCT From the relative expression values, a statement can be made as to whether and to what extent a mutation in the promoter sequence of the crp gene has altered the expression of the crp gene. This change in gene expression (see Example 5) can be correlated with altered strain properties such as cell growth or yields of a
[0047] Metabolic product such as the production of the amino acid L-cysteine (see examples 6 and 7). The open reading frame (ORF, synonymous with cds, coding sequence) is the region of DNA or RNA that begins with a start codon and ends with a stop codon and codes for the amino acid sequence of a protein. The ORF is also referred to as the coding region or structural gene.
[0048] A gene is the DNA segment that contains all the basic information for producing biologically active RNA. A gene contains the DNA segment from which a single-stranded RNA copy is produced through transcription, as well as the expression signals involved in regulating this copying process. Expression signals include, for example, at least one promoter, a transcription start site, a translation start site, and a ribosome binding site. Further expression signals can include a terminator and one or more operators.
[0049] A promoter is a nucleotide sequence located upstream of the 5' end of the cds, which enables the expression of a gene. The promoter is located upstream of the RNA coding region in the direction of synthesis. The promoter contains regions of specific interaction with DNA-binding proteins, which mediate the initiation of gene transcription by RNA polymerase and are referred to as transcription factors.
[0050] A mutation is a change in the genetic material, comprising a change in the DNA sequence and, if protein-coding sequences are affected, also the amino acid sequence of proteins. In the context of the present invention, a mutation comprises the exchange, insertion and / or deletion of one or more nucleotides or one or more amino acids. An exchange refers to the replacement of one or more nucleotides for other nucleotides of a DNA, or of one or more amino acids for other amino acids of a protein. The length of the DNA sequence or the protein sequence remains unchanged. An insertion refers to the incorporation of additional nucleotides into a DNA or of additional amino acids into a protein. The term insertion also includes elongations. In a deletion, one or more nucleotides or parts of a nucleotide sequence are missing.one or more amino acids or even parts of an amino acid sequence. A point mutation occurs when only a single nucleotide or amino acid is replaced by another nucleotide or amino acid. Mutations also include combinations of substitution, deletion, and insertion.
[0051] In the context of this invention, proteins such as Crp begin with a capital letter, while the genes coding sequences of these proteins are designated with a lower case letter (e.g. crp).
[0052] Accordingly, the E. coli crp gene in SEQ ID NO: 1 from nucleotides 565-865 refers to the promoter region of the crp gene, and SEQ ID NO: 1 from nucleotides 866-1495 refers to the cds of the E. coli crp gene. E. coli Crp refers to the protein encoded by this cds, indicated in SEQ ID NO: 2. The protein is the Crp protein.
[0053] The abbreviation WT (Wt) stands for wild type. The term wild-type gene or wild-type promoter refers to the form of the gene or promoter that has arisen naturally through evolution and is present in the wild-type genome. The DNA sequence of wt genes and wt promoters is publicly accessible in databases such as NCBI (National Center for Biotechnology Information, US National Library of Medicine). Alleles are defined as the states of a gene that can be converted into one another through mutation, i.e., through changes in the nucleotide sequence of the DNA. The gene that occurs naturally in a microorganism is called the wild-type allele, and the variants derived from it are called mutated alleles of the gene.
[0054] Homologous genes or homologous sequences are understood to mean that the DNA sequences of these genes or DNA segments are at least 80%, preferably at least 90% and particularly preferably at least 95% identical.
[0055] The degree of DNA identity is determined by the program "nucleotide blast," found at http: / / blast.ncbi.nlm.nih.gov / , which is based on the blastn algorithm. The preset parameters were used as algorithm parameters for the alignment of two or more nucleotide sequences.
[0056] The preset general parameters are: Max target sequences = 100; Short queries = "Automatically adjust parameters for short input sequences"; Expect Threshold = 10; Word size = 28; Automatically adjust parameters for short input sequences = 0. The corresponding preset scoring parameters are: Match / Mismatch Scores = 1,-2; Gap Costs = Linear.
[0057] The program "protein blast" on the website http: / / blast.ncbi.nlm.nih.gov / is used to compare protein sequences. This program uses the blastp algorithm. The preset parameters were used as algorithm parameters for aligning two or more protein sequences. The preset general parameters are: Max target sequences = 100; Short queries = "Automatically adjust parameters for short input sequences"; Expect Threshold = 10; Word size = 3; Automatically adjust parameters for short input sequences = 0. The preset scoring parameters are: Matrix = BLOSUM62; Gap Costs = Existence: 11; Extension: 1; Co 12111 / Reu; Compositional adjustments = Conditional compositional score matrix adjustment. In the microorganisms according to the invention with a deregulated cysteine biosynthesis pathway, the relative expression of the crp gene is preferably limited to a 2 -ΔΔCT-value of at least 0.91, particularly preferably to a 2 -ΔΔCT -value of at least 0.5 and particularly preferably to a 2 -ΔΔCT -value of 0.03, whereby the expression of the crp gene in microorganisms with wild-type promoter is limited to a 2 -ΔΔCT -value of 1.00. The relative expression of the crp gene is preferably determined as described in Example 5. If the expression of the crp gene with wild-type promoter is determined with a 2 -ΔΔCT -value of 1.00 is defined as 100% gene expression of the crp gene, then the crp gene expression of the microorganisms according to the invention with a reduced value of at least 0.91 2 -ΔΔCT - Value maximum 91%, with a 2- ΔΔCT -value maximum 50% and with a minimum reduced to 0.03 2 -ΔΔCT-Value a maximum of 3% of the expression of the crp gene with a wild-type promoter. This means that the method is preferably characterized in that the crp expression of the microorganism strain with the modified crp promoter sequence is reduced by at least 9% compared to a corresponding microorganism strain with a wt crp promoter sequence, and the yield of L-cysteine in g / l is increased by at least 10% (w / v) when using the microorganism strain. "Compared to / in comparison to / related to the (corresponding) expression of the crp gene with wild-type promoter (activity of the crp wild-type promoter, or WT expression) means, in the context of this invention, in comparison to the activity of the crp promoter which corresponds to the non-mutated form of the crp promoter from a microorganism, ie of the crp promoter which Co 12111 / Reu naturally arose through evolution and is present in the wild-type genome of this microorganism.Microorganism strains suitable for the fermentative production of L-cysteine, L-cystine, or thiazolidine include all microorganisms that contain a deregulated cysteine biosynthesis pathway leading to the synthesis of cysteine, cystine, or thiazolidine. Such strains are disclosed, for example, in EP 0 885 962 B1, EP 1382 684 B1, EP 1220 940 B2, EP 1769 080 B1, EP 2138 585 B1, and WO 2021 / 259491.The microorganism strain with a deregulated cysteine biosynthesis pathway is characterized by at least one of the following changes: a) The microorganism strain is characterized by a modified serA gene coding for a 3-phosphoglycerate dehydrogenase (SerA) with a feedback inhibition by L-serine that is reduced by at least a factor of two compared to the corresponding wild-type enzyme (as described, for example, in EP 1950 287 B1), whereby the SerA enzyme activity can be determined photometrically by the oxidation of NADH dependent on the SerA substrate 3-phospho-hydroxypyruvate, as described, for example, by McKitrick and Pizer, J. Bacteriol. (1980) 141: 235 - 245.Particularly preferred variants of 3-phosphoglycerate dehydrogenase (serA) have a feedback inhibition by L-serine that is reduced by at least a factor of 5, particularly preferably by at least a factor of 10 and, in a further preferred embodiment, by at least a factor of 50, compared to the corresponding wild-type enzyme. and / or b) The microorganism strain contains a modified cysE gene coding for a serine O-acetyl transferase (CysE) which, compared to the corresponding wild-type enzyme, has a feedback inhibition by cysteine reduced by at least a factor of two (as described, for example, in EP 0858 510 B1 or Nakamori et al. 1998 (see above), wherein the CysE enzyme activity can be determined photometrically by the consumption of the CysE substrate acetyl-CoA as a result of the reaction with L-serine to form O-acetyl-L-serine, as described, for example, by Nakamori et al. 1998 (see above).
[0058] Particularly preferred variants of serine O-acetyl transferase (cysE) have, compared to the corresponding wild-type enzyme, a feedback inhibition by cysteine reduced by at least a factor of 5, particularly preferably by at least a factor of 10 and, in a further preferred embodiment, by at least a factor of 50. and / or c) The microorganism strain has, by overexpression of an efflux gene, an increased cysteine export from the cell by at least a factor of two compared to the corresponding wild-type cell, wherein the cysteine export can be determined by photometric measurement of the extracellular cysteine content according to Gaitonde, Biochem. J. (1967) 104: 627 - 633 (comprising cysteine, cystine and the adduct 2-methyl-thiazolidine-2,4(R)-dicarboxylic acid formed from cysteine and pyruvate), as described e.g. in EP 0885 962 Bl.
[0059] The overexpression of an efflux gene preferably leads to an increased cysteine export from the cell by at least a factor of 5, particularly preferably by at least a factor of 10, especially preferably by at least a factor of 20, compared to a wild-type cell.
[0060] The efflux gene preferably originates from the group ydeD (see EP 0885 962 B1), yfiK (see EP 1382 684 B1), cydDC (see WO 2004 / 113373 A1), bcr (see US 2005-221453 AA) and emrAB (see US 2005-221453 AA) of E. coli or the corresponding homologous gene from another microorganism. and / or d) The microorganism strain can further be characterized in that at least one cysteine-degrading enzyme is attenuated to such an extent that only a maximum of 50% of this enzyme activity is present in the cell compared to a wild-type cell. The cysteine-degrading enzyme preferably originates from the group tryptophanase (TnaA) and cystathionine ß-lyase (MalY, MetC).
[0061] Such strains are known, for example, from EP 0858 510 Bl and EP 0 885 962 Bl.
[0062] The microorganism strains described in the previous sections, which are suitable for the fermentative production of L-cysteine, L-cystine, or thiazolidine, have their cysteine metabolism deregulated to such an extent that they produce an increased amount of L-cysteine compared to a microorganism strain whose cysteine metabolism is not deregulated. This means that a cysteine-producing strain, or a microorganism strain capable of cysteine production, is characterized by a deregulated cysteine biosynthesis pathway. Since the amount of L-cysteine in the cells of a microorganism strain whose cysteine metabolism is not deregulated in the culture mixture is approximately 0 g / l, an increased amount preferably means any amount that exceeds 0.05 g / l of L-cysteine measured in the culture mixture after 24 hours of cultivation.
[0063] The amount of cysteine can be quantified, for example, using the colorimetric test of Gaitonde 1967 (see above), as described in Example 6 (cf. Table 2, strain W3110 and strain W3110 x pCys).
[0064] The microorganism strain according to the invention with a deregulated cysteine biosynthesis pathway, a mutated crp promoter sequence, and thus reduced relative expression of the crp gene produces, compared to the corresponding microorganism strain, i.e., the latter also features a deregulated cysteine biosynthesis pathway, with expression of the crp gene with a wild-type promoter, an increased amount of a substance selected from L-cysteine, L-cystine, and thiazolidine, which represents a major advantage. As demonstrated in Table 3 (Example 7), increasing mutation of the crp promoter sequence up to the complete deletion of the crp promoter, i.e., a 9% to 100% reduced relative expression of the crp gene, leads to significantly higher yields of total cysteine, i.e., the sum of the cysteine, cystine, and thiazolidine produced, in a fermentative process.The comparison is always made between a microorganism strain with a mutated promoter sequence of the crp gene and the corresponding microorganism strain with a wt promoter sequence of the crp gene, ie both microorganism strains are deregulated in their cysteine metabolism.
[0065] When cysteine is mentioned in the present invention, this always refers to L-cysteine or one of its derivatives selected from L-cystine or thiazolidine. This means that the amount of cysteine produced preferably refers to total cysteine, i.e., the sum of the L-cysteine, L-cystine, and thiazolidine produced. For example, the resulting L-cystine can be reduced to L-cysteine and subsequently included in the measurement of produced cysteine. If, for example, the colorimetric test of Gaitonde (see above) is used for the determination, this test cannot distinguish between L-cysteine and the condensation product of cysteine and pyruvate, 2-methylthiazolidine-2,4-dicarboxylic acid (thiazolidine), described in EP 0885 962 B1, under the strongly acidic reaction conditions, and thiazolidine is also included in the measurement of produced cysteine.According to the invention, the microorganism strain produces an increased amount of a substance selected from L-cysteine, L-cystine and thiazolidine, preferably L-cysteine and L-cystine and particularly preferably L-cysteine.
[0066] Preferably, the microorganism strain is characterized in that the amino acid sequence of the Crp protein is not mutated. This means that the amino acid sequence of the Crp protein is the wt sequence shown in SEQ ID NO: 2. To achieve this, the coding sequence of Crp comprises only so-called silent mutations or no mutation at all. Due to the degenerate genetic code, silent mutations are defined as changes to a cds that do not change the derived amino acid sequence. This means that the Crp cds is identical to the wt DNA sequence available in the NCBI database for Crp of the corresponding organism or comprises only silent mutations and encodes a non-mutated Crp protein with the wt protein sequence. In the present invention, it is particularly preferred that only the promoter sequence of the Crp gene of a microorganism strain is mutated. Preferred are mutations of the promoter sequence of the crp gene from E.coli, comprising the sequence SEQ ID NO: 1, nt 565-865, while the crp-cds, comprising the sequence SEQ ID NO: 1, nt 866-1498, is not mutated or comprises only silent mutations and encodes a protein with the protein sequence SEQ ID NO: 2.
[0067] For the purposes of the invention, mutations in the crp promoter sequence include changes such that a) the crp promoter sequence of the crp gene is partially or completely deleted and / or b) the crp promoter sequence of the crp gene is altered by one or more insertions or 5' or 3' elongations and / or c) the crp promoter sequence of the crp gene contains one or more point mutations, with the result that the expression of the crp gene is reduced, i.e. weakened or completely suppressed. As already described above, reduced means that the crp gene expression of the microorganisms according to the invention is preferably a maximum of 91%, particularly preferably a maximum of 50% and especially preferably a maximum of 3% of the expression of the crp gene with a wild-type promoter. In a particularly preferred embodiment, no crp gene expression is detectable in the microorganisms according to the invention.
[0068] Particularly preferably, in the above-mentioned cases of reduced crp gene expression, the crp protein does not exhibit any mutation, ie the amino acid sequence is unchanged compared to the Wt.
[0069] Within the meaning of the invention, any combination of the genetic modifications listed in a) to c) in the promoter of the CRP gene is also possible. In summary, within the meaning of the invention, the expression of the CRP gene is attenuated or completely suppressed by modifications of the CRP promoter. Attenuation of CRP expression can also be achieved by completely or partially replacing the CRP promoter with an alternative weak promoter.
[0070] Particularly preferably, the modification of the crp promoter in the strain according to the invention is based on complete or partial deletion of the crp promoter or modification of the crp promoter by one or more insertions or 5'- or 3'-elongations, or a combination of deletion and insertion.
[0071] Particularly preferably, the modification of the crp promoter in the strain according to the invention is based on complete or partial deletion of the crp promoter.
[0072] Preferably, the microorganism strain is characterized in that the mutation in the crp promoter sequence comprises at least one deletion or insertion, particularly preferably at least one deletion.
[0073] In a particularly preferred embodiment, the mutation in the crp promoter sequence, which preferably comprises the sequence shown in SEQ ID NO: 1, nt 565-865, is at least one deletion or insertion, and the coding sequence of crp is not mutated. Preferably, the microorganism strain is characterized in that at least nt 565-624 of the crp promoter sequence shown in SEQ ID NO: 1, nt 565-865, is deleted. In this case, the crp promoter sequence comprises a maximum of nt 625-865 from SEQ ID NO: 1.
[0074] Particularly preferably, the microorganism strain is characterized in that the crp promoter sequence shown in SEQ ID NO: 1 nt 565-865 is completely deleted.
[0075] Particularly preferred embodiments, including insertion, deletion and elongation, are shown in the examples:
[0076] - for complete or partial deletion of the crp promoter sequence see Example 2,
[0077] - for modification of the crp promoter sequence by one or more insertions, see Example 1,
[0078] - to modify the crp promoter sequence in a way that leads to the weakening or complete inhibition of promoter activity, see Example 5.
[0079] Preferably, the microorganism strain is characterized in that it is a strain from the Enterobacteriaceae or Corynebacteriaceae family, particularly preferably a strain from the Enterobacteriaceae family. Such strains are commercially available, for example, from the DSMZ German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig).
[0080] The microorganism strain is preferably selected from the group consisting of Escherichia coli, Pantoea ananatis, and Corynebacterium glutamicum, particularly preferably from the group consisting of Escherichia coli and Pantoea ananatis. The microorganism strain is particularly preferably a strain of the species Escherichia coli. The E. coli strain is preferably selected from E. coli K12, particularly preferably E. coli K12 W3110. Such strains are commercially available, for example, from the DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig), including E. coli K12 W3110 DSM 5911 (id. ATCC 27325) and Pantoea ananatis DSM 30070 (id. ATCC 11530).
[0081] The crp gene from E. coli K12, for example, is accessible in the NCBI gene database as an entry in the E. coli GenBank Reference Sequence with accession number NC_000913.3, nt 3485255 - nt 3486950 (SEQ ID NO: 1). The crp gene from Pantoea ananatis, for example, is accessible in the NCBI gene database as an entry in the P. ananatis GenBank Reference Sequence with accession number NC_017554.1, nt 430825 - nt 431818 (crp-cds: nt 430883 - nt 431515; gene identification number 57266449).
[0082] In a preferred embodiment, the microorganism strain is characterized in that the mutated crp promoter sequence is selected from the group consisting of the promoter sequences of the crp gene from Escherichia coli, the crp gene from Pantoea ananatis and a sequence homologous to these sequences, the term homologous sequence being as defined above.
[0083] The crp gene is preferably the crp gene from E. coli with the promoter region indicated in SEQ ID NO: 1 nt 565-865 and the crp-cds indicated in SEQ ID NO: 1, nt 866-1495, encoding a Crp protein with the amino acid sequence indicated in SEQ ID NO: 2.
[0084] Accordingly, the microorganism strain is preferably characterized in that the expressed Crp protein is SEQ ID NO: 2. This means that the Crp protein being expressed has the wt sequence (SEQ ID NO: 2), and the mutation only affects the Crp promoter sequence (SEQ ID NO: 1 nt 565-865). The production strain according to the invention can also be further optimized to further improve cysteine production. The optimization can, for example, be carried out genetically by additionally expressing one or more genes that are suitable for improving production properties. These genes can be expressed in a manner known per se as separate gene constructs or combined as an expression unit (as a so-called operon) in the production strain.The production strain can be further optimized by reducing the expression of the crp gene and inactivating other genes whose gene products negatively affect cysteine production. However, optimization is also possible in a conventional manner through mutagenesis and selection of strains with improved cysteine production.
[0085] In an alternative approach, it is also conceivable that the attenuation or complete suppression of the expression of the crp gene is achieved by adding an inhibitor, be it a chemical or protein inhibitor, whereby the inhibitor inhibits the activity of the crp promoter and not the activity of the crp protein.
[0086] Various methods for introducing changes to the promoter of the crp gene are known to those skilled in the art. In the simplest case, the starting strain can be subjected to mutagenesis in a known manner (e.g., chemically using mutagenic chemicals such as N-methyl-N'-nitro-N-nitrosoguanidine or physically using UV irradiation), whereby mutations are randomly generated in the genomic DNA and the desired mutant with an altered crp promoter is then selected from the multitude of mutants generated, e.g., after isolating the mutants, by quantitatively determining the crp protein (e.g., immunologically by Western blot with a crp-specific antibody) or by quantitatively determining crp expression using, for example, RT-PCR. In this case, only mutants with an altered crp promoter are selected, while the crp cds remains unchanged and corresponds to the wild-type sequence.
[0087] In contrast to the complex, random mutagenesis and selection of the desired mutant with an altered crp promoter, the promoter of the crp gene can be specifically modified in a simpler manner, e.g., through the known mechanism of homologous recombination. Cloning systems for targeted gene inactivation using homologous recombination are known to those skilled in the art and are commercially available, as disclosed, for example, in the user manual for the "Quick and Easy E. coli Gene Deletion Kit," based on Red® / ET® technology from Gene Bridges GmbH (see "Technical Protocol, Quick & Easy E. coli Gene Deletion Kit, by Red® / ET® Recombination, Cat. No. K006, Version 2.3, June 2012" and the literature cited therein).
[0088] According to the current state of the art, the CRP promoter or a portion of the promoter can be isolated and a foreign DNA cloned into the CRP promoter, thereby altering the promoter sequence. A DNA construct suitable for the targeted modification of the CRP promoter can therefore consist of a 5' DNA segment that is homologous to the genomic CRP promoter, followed by a gene segment containing the foreign DNA, and then a 3' DNA segment that is in turn homologous to the genomic CRP promoter.
[0089] The region of the crp promoter that is considered for homologous recombination can encompass not only the sequence region of the promoter. The region in question can also include DNA sequences flanking the promoter, namely the 5' flanking sequence before the start of the crp promoter (e.g., nt 1-564 in SEQ ID NO: 1). DNA sequences in the 3' region of the crp promoter relate to the cds of the crp gene (crp-cds, nt 866-1498 in SEQ ID NO: 1), whereby it is excluded that the cds of the crp gene is altered by homologous recombination. The foreign DNA is preferably a selection marker expression cassette, e.g., selected from the class of antibiotic resistance genes.
[0090] Another such system for targeted gene inactivation based on homologous recombination is a method for genetic modification known to the person skilled in the art and described in Examples 1 and 2. It is based on a combination of Lambda Red recombination with counterselection screening. This system is described, for example, in Sun et al., Appl. Env. Microbiol. (2008) 74: 4241-4245. A DNA construct is used to inactivate, for example, the crp promoter, starting from the 5' end, consisting of a sequence homologous to the crp gene (comprising the 5' region of the crp promoter) followed by two expression cassettes in any order, consisting of a) an expression cassette of the selection marker, selected from the class of antibiotic resistance genes and b) an expression cassette of the sacB gene, coding for the enzyme levansucrase and finally followed by another sequence homologous to the crp gene (comprising, for example,Sequences of the crp-cds flanking the crp promoter 3'.
[0091] In a first step, the DNA construct is transformed into the production strain, and antibiotic-resistant clones are isolated. The resulting clones are characterized by the fact that they cannot grow on sucrose due to the inclusion of the sacB gene. Using the principle of counterselection, the two marker genes can be removed by replacing the two marker genes with a suitable DNA fragment through homologous recombination in a second step. The clones obtained in this step can then grow on sucrose again and are then sensitive to the antibiotic again. This method is used in Examples 1 and 2 for the targeted shortening of the crp promoter of E. coll (SEQ ID NO: 1, nt 565-865). A DNA fragment suitable for this step comprises, starting from the 5' end, a nucleotide sequence leading to the target gene, e.g.The crp gene is a homologous sequence of at least 20 nt in length, followed by a DNA segment containing the desired modified DNA sequence, e.g., a truncated crp promoter, and finally another sequence of at least 20 nt in length that is homologous to the target gene, e.g., the crp gene. The DNA fragment can be produced chemically, e.g., by gene synthesis or, as in Example 2, from individual DNA fragments using the well-known so-called OE-PCR (Overlap Extension PCR, as described, e.g., in Hilgarth and Lanigan, MethodsX (2020) 7: 100759, https: / / doi.org / 10.1016 / j.mex.2019.12.001).
[0092] As an example of a strain according to the invention which exhibits attenuated crp expression due to a combination of insertion of the Kan-sacB cassette and deletion in the crp promoter, the following E. coli strain is disclosed in the examples: W3110-crp ::kan-sacB. In W3110-crp ::kan-sacB, the 3.2 kb Kan-sacB cassette is inserted in the crp promoter between nt 640 and nt 714 of SEQ ID NO: 1, thereby simultaneously deleting 73 nt (SEQ ID NO: 1, nt 641 - nt 713) of the crp promoter (see Example 1). As a result of this change in the crp promoter, the relative expression of the crp gene in the strain W3110-crp::kan-sacB x pCys transformed with the plasmid pCys was still 0.33-fold, ie still 33% of the expression of the strain W3110 x pCys with wild-type crp promoter, normalized to 1 or 100% (see Example 5, Table 1).
[0093] As examples of strains according to the invention which have attenuated crp expression due to a truncation of the crp promoter, the following E. coli strains are disclosed in the examples (Example 2):
[0094] W3110-crpP-del: Deletion nt 565 - nt 865 from SEQ ID NO: 1 W3110-crp-Preg: Deletion nt 565 - nt 713 from SEQ ID NO: 1 W3110-crp-Preg2: Deletion nt 565 - nt 675 from SEQ ID NO: 1 W3110-crp-Preg3: Deletion nt 565 - nt 624 from SEQ ID NO: 1
[0095] As a result of these shortenings of the crp promoter, the relative expression of the crp gene in the strains transformed with the plasmid pCys was still the following fractions of the expression of the strain W3110 x pCys with wild-type crp promoter, normalized to 1 (see Example 5, Table 1): In E. coli W3110-crpP-del x pCys with a completely deleted crp promoter (deletion nt 565 - nt 865 from SEQ ID NO: 1), the relative crp expression was still 0.03 times that of the wild-type crp promoter. In E. coli W3110-crp-Preg x pCys, the crp promoter was shortened by 149 nt (deletion nt 565 - nt 713 from SEQ ID NO: 1). The relative CRP expression was still 0.05 times that of the wild-type CRP promoter. In E. coli W3110-CRP-Preg2 x pCys, the CRP promoter was shortened by 111 nt (deletion nt 565 - nt 675 from SEQ ID NO: 1). Relative CRP expression was still 0.5 times that of the wild-type CRP promoter. In E.coli W3110-crp-Preg3 x pCys, the crp promoter was shortened by 60 nt (deletion nt 565 - nt 624 from SEQ ID NO: 1). Relative crp expression was still 0.91 times that of the wild-type crp promoter.
[0096] These results show that the relative expression of the crp gene could be reduced by progressively shortening the crp promoter from 0.91-fold to 0.03-fold of the expression of the wt promoter, or attenuated to 0.33-fold by a combination of insertion and deletion.
[0097] For the E. coli crp gene, it is preferred that by deletion or a combination of insertion and deletion the relative expression of the crp gene is attenuated from the value 1 for the wild-type crp promoter to at least 0.91-fold, more preferably at least 0.5-fold and especially preferably at least 0.33-fold. The strain of the invention, characterized by alteration of the crp promoter in a manner that leads to attenuation of crp expression, such as the E. coli strains W3110- crp::kan-sacB, W3110- crpP-del, W3110- crp-Preg, W3110- crp-Preg2 or W3110- crp-Preg3, can be produced by using the previously described combination of lambda red recombination with a counter-selection screening for genetic modification (see, for example, Sun et al. 2008, supra), as disclosed in Examples 1 and 2.
[0098] Particularly preferred strains are E. coli W3110-crp-Preg2 and E. coli W3110-crp-Preg3 (described in Example 2).
[0099] The invention further relates to a process comprising the production of at least one compound selected from L-cysteine, L-cystine, and thiazolidine, characterized in that the microorganism strains according to the invention are used. The process can involve cultivating the microorganism strains according to the invention in a shake flask (laboratory scale) or fermenter (production scale), with a process in a fermenter (production scale) being preferred. Although a specific medium and pH are also specified in shake flask culture and cultured in the presence of oxygen and under constant agitation (shaking), more defined conditions regarding the medium (e.g., addition of components or regulation of the fermenter volume by partially draining fermenter broth), temperature, pH, oxygen supply, and medium mixing can be adjusted and regulated in the fermenter. This meansBoth shake flask culture and fermenter culture are referred to as fermentation processes and differ in scale. In the fermentation process, the microbial production strain is induced to grow and produce the metabolite. The smaller-scale culture can also be used as a pre-culture for inoculating a larger-scale culture. The state of the art does not disclose any processes or production strains in which cysteine production can be improved by attenuating CRP expression through altering the CRP promoter sequence.
[0100] L-cysteine is formed as the primary product of the process according to the invention. Oxidation produces sparingly soluble L-cystine according to equations (1) to (3), which accumulates as a precipitate during fermentation (EP 0885 962 B1, EP 2 707 492 B1). Thiazolidine is formed by the formation of an adduct with pyruvate, which accumulates in the culture supernatant (EP 0885 962 B1).
[0101] Preferably, the process is characterized in that the formed L-cysteine, L-cystine, or thiazolidine is isolated. The isolation of L-cysteine is disclosed in EP 2 699544 B1 and EP 1 958 933 B1. Precipitated L-cystine can be separated from the remaining components, for example, using a decanter, followed by dissolving the crude product with a mineral acid, clarifying the crude product solution by centrifugation or filtration, decolorizing the solution, and precipitation crystallization (EP 2 707492 B1).
[0102] The yield of total cysteine is defined in this invention as the sum of the cysteine, cystine, and thiazolidine produced. This is determined from the entire culture mixture as described in Example 7. It can be quantified, for example, using the colorimetric test of Gaitonde (Gaitonde, MK (1967), Biochem. J. 104, 627-633).
[0103] As shown in the examples of the present application, attenuation of crp expression in a microorganism strain suitable for cysteine, cystine, or thiazolidine production with deregulated cysteine biosynthesis is capable of significantly increasing the yields of total cysteine, i.e., the sum of the cysteine, cystine, and thiazolidine produced, in a fermentative process. This was completely unexpected given the state of the art.
[0104] It is surprising that the fermentation of microorganism strains with deregulated cysteine biosynthesis pathway and reduced expression of the crp gene by mutation of the crp promoter sequence relative to the expression of the crp gene with wild-type promoter sequence leads to significantly higher cysteine yields. As evidence, Table 3 of Example 7 summarizes that in the fermentation of the E. coli strains W3110-crp::kan-sacB x pCys with 0.33-fold relative expression of the crp gene, W3110-crp-Preg2 x pCys with 0.5-fold relative expression of the crp gene and W3110-crp-Preg3 x pCys with 0.91-fold relative expression of the crp gene, significantly higher cysteine yields could be achieved compared to the corresponding wild-type strain W3110 x pCys with a relative crp expression of 1. Contrary to the state of the art and unexpected for the person skilled in the art, the attenuation of the expression of the crp gene by complete or partial deletion, ora combination of insertion and deletion in the crp promoter to produce improved cysteine-producing strains.
[0105] This new and inventive measure for improving cysteine-producing strains was confirmed by the results summarized in Table 2 of Example 6, in which the attenuation of the expression of the crp gene by deletion, or a combination of insertion and deletion in the crp promoter, already led to improved cysteine yields in shake flask culture. Table 2 of Example 6 further illustrates that in strains with strongly attenuated crp expression, such as W3110-crpP-del x pCys (0.03-fold relative crp expression compared to W3110 x pCys) and W3110-crp-Preg x pCys (0.05-fold relative expression compared to W3110 x pCys), cell growth (OD 600 / ml in Table 2). Nevertheless, cysteine production was significantly improved, which was even more pronounced when cysteine production was related to growth (cysteine mg / OD in Table 2), corresponding to an increase of 285.5% and 360%, respectively.
[0106] For the skilled person, the attenuation of the expression of the crp gene by deletion, or a combination of insertion and deletion in the crp promoter, thus represents a new, useful measure for improving cysteine production in other cysteine-producing strains. In the microorganism strain according to the invention, which is suitable for cysteine production and has deregulated cysteine biosynthesis, the expression of the crp gene is accordingly attenuated by deletion, or a combination of insertion and deletion in the crp promoter, and cysteine production is simultaneously increased, whereby a change in the crp-cds is excluded.
[0107] Example 7 demonstrates that a strain capable of cysteine production with deregulated cysteine biosynthesis and attenuated expression of the crp gene by deletion, or a combination of insertion and deletion in the crp promoter, achieves significantly higher cysteine yields in fermentation than a strain containing the WT promoter of the crp gene, whereby the crp-cds remains unchanged in all strains according to the invention.
[0108] In the fermentation process in question, on the one hand, biomass of the production strain according to the invention and, on the other hand, cysteine and its oxidation product cystine are formed. The formation of biomass and cysteine can be temporally correlated or decoupled from each other. Cultivation is carried out in a manner familiar to the person skilled in the art. For this purpose, cultivation can take place in shake flasks (laboratory scale) or in a fermenter (production scale). The microorganism strain is characterized in that it is deregulated in the cysteine biosynthesis pathway and contains at least one mutation in the promoter of the crp gene. At the same time, the strain produces an increased amount of L-cysteine compared to the strain with a wild-type crp promoter. Preferably, the genetic modification in the promoter of the crp gene leads to an increased expression of the crp gene compared to the wild-type crp promoter (100% expression, 2 -ΔΔCT -value = 1) by at least 9% (2 -ΔΔCT-value ≤ 0.91), particularly preferably by at least 50% (2 -ΔΔCT -value ≤ 0.5) and particularly preferably by at least 67% (2 -ΔΔCT -value ≤ 0.33) is reduced.
[0109] The method is preferably characterized in that the crp expression of the microorganism strain with modified crp promoter sequence is reduced by at least 9%, particularly preferably by at least 50% and especially preferably by at least 67% compared to a corresponding microorganism strain with wt crp promoter sequence, and the yield of a substance selected from L-cysteine, L-cystine and thiazolidine in g / l when using the microorganism strain is increased by at least 10% (w / v), particularly preferably by at least 20% (w / v) and especially preferably by at least 50% (w / v). According to the invention, the microorganism strain forms an increased amount of a substance selected from L-cysteine, L-cystine and thiazolidine, preferably L-cysteine and L-cystine and particularly preferably L-cysteine.
[0110] Due to the reduced crp expression, the total cysteine production (volume production in g / L), i.e. of the cysteine, cystine, and thiazolidine produced, is increased by at least 10% (w / v), particularly preferably by at least 20% (w / v), and especially preferably by at least 50% (w / v) when grown in a shake flask or fermenter compared to the control strain with a WT crp promoter. The volume production of the shake flask culture within 24 hours is preferably at least 0.37 g / L (Table 2), and the volume production in the fermentation within 48 hours is preferably at least 15.9 g / L (Table 2).
[0111] 3).
[0112] The process is preferably characterized in that the process is a fermentative process and the fermentation volume is at least 1 L. Particularly preferably, it is greater than 10 L, especially preferably greater than 1000 L, and especially preferably greater than 10,000 L. The fermentative process is particularly preferably a process in a fermenter.
[0113] Growing media are familiar to those skilled in microbial cultivation. They typically consist of a carbon source (C source), a nitrogen source (N source), and additives such as vitamins, salts, and trace elements, as well as a sulfur source (S source), which optimize cell growth and cysteine production.
[0114] C sources are those that can be used by the production strain to form cysteine products. These include all forms of monosaccharides, including C6 sugars (hexoses) such as glucose, mannose, fructose, or galactose, and C5 sugars (pentoses) such as xylose, arabinose, or ribose, as well as all conceivable di- and polysaccharides formed from them, such as sucrose, lactose, maltose, maltodextrin, starch, or the monomers or oligomers released from them by hydrolysis (enzymatic or chemical). Other usable C sources other than sugars or carbohydrates are acetic acid (or acetate salts derived therefrom), ethanol, glycerol, citric acid (and their salts), or pyruvate (and its salts). Gaseous C sources such as carbon dioxide or carbon monoxide are also conceivable.
[0115] Preferred C sources for cultivating the production strains are glucose, fructose, sucrose, mannose, xylose and arabinose, among which glucose and sucrose are particularly preferred and glucose is especially preferred.
[0116] N sources are those that can be used by the production strain for biomass formation. These include ammonia, in gaseous form or in aqueous solution as NH4OH, or its salts such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium acetate, or ammonium nitrate. Other suitable N sources include well-known nitrate salts such as KNO3, NaNO3, ammonium nitrate, Ca(NO3)2, Mg(NO3)2, as well as other N sources such as urea. N sources also include complex amino acid mixtures such as yeast extract, proteose peptone, malt extract, soybean peptone, casamino acids, corn steep liquor (liquid or dried as CSD), as well as NZ amines and yeast nitrogen base.
[0117] The addition of a sulfur source, either as a single addition in batch form or as a continuous feed, is necessary for the efficient production of cysteine and cysteine derivatives. The continuous addition can take place as a pure feed solution or in a mixture with another feed component such as glucose. Suitable sulfur sources are salts of sulfates, sulfites, dithionites, thiosulfates or sulfides, whereby the use of the respective acids is also conceivable if stability is given. Preferred sulfur sources are salts of sulfates, sulfites, thiosulfates and sulfides, among which particularly preferred salts of sulfates and thiosulfates and especially preferred salts of thiosulfate, such as sodium thiosulfate and ammonium thiosulfate.
[0118] Cultivation can be carried out in so-called batch mode, whereby the cultivation medium is inoculated with a starter culture of the production strain and then cell growth occurs without further feeding of nutrient sources. Cultivation can also be carried out in so-called fed-batch mode, whereby after an initial growth phase in batch mode, additional nutrient sources are added (feed) to compensate for their consumption. The feed can consist of the C source, the N source, the sulfur source, one or more vitamins or trace elements important for production, or a combination of the above. The feed components can be added together as a mixture or separately in individual feed lines. In addition, other media components as well as additives that specifically increase cysteine production can be added to the feed.The feed can be applied continuously or in batches (discontinuously), or in a combination of continuous and discontinuous feed. Fed-batch cultivation is preferred.
[0119] Preferred C sources in feed are glucose, sucrose, and plant hydrolysates containing glucose or sucrose, as well as mixtures of the preferred C sources in any ratio. Glucose is a particularly preferred C source in feed.
[0120] Preferably, the carbon source is added to the culture in such a way that the carbon source content in the fermenter during the production phase does not exceed 10 g / L. A maximum concentration of 2 g / L is preferred, particularly preferably 0.5 g / L, and especially preferably 0.1 g / L.
[0121] Preferred N sources in the feed are ammonia, gaseous or in aqueous solution as NH4OH and its salts ammonium sulfate, ammonium phosphate, ammonium acetate and ammonium chloride, as well as urea, KNO3, NaNO3 and ammonium nitrate, yeast extract, proteose peptone, malt extract, soy peptone, casamino acids, corn steep liquor as well as NZ amines and yeast nitrogen base, among which ammonia or ammonium salts, yeast extract, soy peptone or corn steep liquor (liquid or in dried form) are particularly preferred. Preferred sulfur sources in the feed are salts of sulfates, sulfites, thiosulfates and sulfides, among which salts of sulfates and thiosulfates are particularly preferred and especially preferred salts of thiosulfate, such as sodium thiosulfate and ammonium thiosulfate.
[0122] Further media additives include salts of the elements phosphorus, chlorine, sodium, magnesium, nitrogen, potassium, calcium, iron, and, in trace amounts (i.e., in pM concentrations), salts of the elements molybdenum, boron, cobalt, manganese, zinc, copper, and nickel. Furthermore, organic acids (e.g., acetate, citrate), amino acids (e.g., isoleucine), and vitamins (e.g., vitamin B1, vitamin B6) can be added to the medium.
[0123] Cultivation takes place under pH and temperature conditions that favor the growth and cysteine production of the production strain. The useful pH range is from pH 5 to pH 9. A pH range of pH 5.5 to pH 8 is preferred. A pH range of pH 6.0 to pH 7.5 is particularly preferred.
[0124] The preferred temperature range for growth of the production strain is 20°C to 40°C. The temperature range from 25°C to 37°C is particularly preferred, and from 28°C to 34°C is especially preferred.
[0125] The production strain can grow optionally without oxygen (anaerobic cultivation) or with oxygen (aerobic cultivation). Aerobic cultivation with oxygen is preferred.
[0126] During aerobic cultivation of the strain according to the invention for cysteine production, an oxygen saturation of at least 10% (v / v), preferably at least 20% (v / v), and particularly preferably at least 30% (v / v) is established. The oxygen saturation in the culture is regulated automatically according to the state of the art via a combination of gas supply and stirring speed.
[0127] The oxygen supply is ensured by the introduction of compressed air or pure oxygen. Aerobic cultivation with the introduction of compressed air is preferred. The useful range of compressed air supply for aerobic cultivation is 0.05 vvm to 10 vvm (vvm: introduction of compressed air into the fermentation mixture expressed in liters of compressed air per liter of fermentation volume per minute). A compressed air introduction of 0.2 vvm to 8 vvm is preferred, particularly preferred is 0.4 to 6 vvm, and especially preferred is 0.8 to 5 vvm.
[0128] The maximum stirring speed is 2500 rpm, preferably 2000 rpm and particularly preferably 1800 rpm.
[0129] The cultivation time is between 10 h and 200 h. A cultivation time of 20 h to 120 h is preferred. A cultivation time of 30 h to 100 h is particularly preferred.
[0130] Cultivation mixtures obtained by the process described above contain L-cystine in precipitated form, which is formed from the primary product L-cysteine according to equations (1) to (3) (EP 0885 962 B1, EP 2 707492 B1). Depending on the fermentation conditions, L-cysteine can also be the main product, which accumulates dissolved in the culture supernatant (EP 2 726625 B1). The cysteine or cystine contained in the cultivation mixtures can either be used directly without further processing or isolated from the cultivation mixture.
[0131] The process is preferably characterized in that the cysteine or cystine formed is isolated. Known process steps are available for isolating cysteine and cystine, including centrifugation, decantation, dissolving the crude product with a mineral acid, filtration, extraction, chromatography, crystallization, or precipitation. These process steps can be combined in any desired way to isolate the cysteine in the desired purity. The desired degree of purity depends on the subsequent use. Processes for isolating L-cysteine are disclosed in EP 2 699 544 B1 and EP 1958 933 B1. The procedure for isolating L-cystine is described in EP 2 707 492 B1.
[0132] The cystine obtained during processing can be reduced to cysteine for further use. A process for reducing L-cystine to L-cysteine in an electrochemical process is disclosed in EP 0235 908.
[0133] Various analytical methods for identifying, quantifying and determining the purity of the cysteine or cystine product are available, including spectrophotometry, NMR, gas chromatography, HPLC, mass spectroscopy, gravimetry or a combination of these analytical methods.
[0134] The invention also allows the production of improved microorganism strains for the fermentative production of compounds whose biosynthesis starts from 3-phosphoglycerate and leads via L-serine to L-cysteine and L-cystine. This also includes microorganism strains for the fermentative production of derivatives of L-serine and L-cysteine, including phosphoserine, O-acetylserine, N-acetylserine, and thiazolidine.
[0135] The figures show the plasmids used in the examples.
[0136] Fig. 1 shows the 6.3 kb vector pKD46 used in Example 1 and Example 2. Fig. 2 shows the 5 kb vector pKan-SacB used in Example 1.
[0137] Fig. 3 shows the 7.1 kb vector pCys used in Example 3.
[0138] Abbreviations used in the figures: bla: gene conferring resistance to ampicillin (ß-lactamase) kanR: gene conferring resistance to kanamycin araC: araC gene (repressor gene)
[0139] P araC: promoter of the araC gene
[0140] P araB: promoter of the araB gene
[0141] Yarn: Lambda Phage Gam recombination gene
[0142] Bet: Lambda Phage Bet recombination gene
[0143] Exo: Lambda Phage Exo recombination gene
[0144] ORI101: Temperature-sensitive origin of replication
[0145] RepA: Gene for plasmid replication protein A sacB: Levansucrase gene pr-f: Binding site f for primer (forward) pr-r: Binding site r for primer (reverse)
[0146] OriC: Origin of replication C
[0147] TetR: Gene that confers resistance to tetracycline
[0148] P15A LOCATION: Origin of replication serA317: serA (3-phosphoglycerate dehydrogenase gene, encodes
[0149] Amino acid 1 to 317) cds cysE X: cysE (serine O-acetyltransferase gene, feedback-resistant) cds
[0150] ORF306: ydeD (cysteine efflux gene) cds
[0151] The invention is further explained by the following examples, without being limited by them: Example 1: Production of the strain E. coli W3110-crp ::kan- sacB
[0152] Escherichia coii K12 W3110 was used as the starting strain for DNA isolation and strain development (available under strain number DSM 5911 from the DSMZ German Collection of Microorganisms and Cell Cultures GmbH).
[0153] The target of the genetic modification was the promoter region of the crp gene from E. coli. The DNA sequence of the crp gene region, including the cds of the divergently expressed yhfA gene, the crp promoter region, and the cds of the crp gene from E. coli K12 (Genbank NCBI Reference Sequence NC_000913.3, nt 3485255 - nt 3486950), is disclosed in SEQ ID NO: 1.
[0154] Nucleotides 163 - 564 (designated E. coli yhfA) comprise, in reverse complementary form, the cds of the yhfA gene.
[0155] Nucleotides 866 - 1495 (designated E. coli crp) comprise the cds of the crp gene, encoding a protein with the amino acid sequence of SEQ ID NO: 2.
[0156] The intergenic region between the divergently expressed genes yhfA and crp, encompassing nucleotides 565–865 in SEQ ID NO: 1, contains the promoter sequence of the crp gene. Analysis of the crp promoter region is described in Hanamura and Ajba 1991 (see above).
[0157] The strain E. coli W3110-crp::kan-sacB, characterized by integration of the kan-sacB cassette in the crp promoter, was produced by using the combination of lambda-red recombination and counter-selection screening for genetic modification known to those skilled in the art (see, for example, Sun et al. 2008, supra).
[0158] The procedure was as follows: 1. E. coli W3110 was transformed with the plasmid pKD46, and transformants were selected on LBamp plates (10 g / L tryptone from GIBCO™, 5 g / L yeast extract from BD Biosciences, 5 g / L NaCl, 1.5% agar, 100 mg / L ampicillin from Sigma-Aldrich). An ampicillin-resistant clone was selected and designated E. coli W3110 x pKD46.
[0159] The 6.3 kb plasmid pKD46 (so-called "Red Recombinase" plasmid, Fig. 1) is disclosed in the "GenBank" gene database under the accession number AY048746.1. 2. The 3.2 kb Kan-sacB cassette was isolated from the plasmid pKan-SacB by PCR with the primers crp-9f (SEQ ID NO: 3) and crp-10r (SEQ ID NO: 4).
[0160] The 5 kb plasmid pKan-sacB (Fig. 2) contains expression cassettes for both the kanamycin (kanR) resistance gene and the sacB gene, encoding the enzyme levansucrase. The E. coli kanamycin resistance gene, encoding an aminoglycoside phosphotransferase, is disclosed in the NCBI database under accession number SH02_03400. The B. subtilis sacB gene is disclosed in the NCBI database under accession number 936413.
[0161] The primer crp-9f contained 50 nt from the crp promoter region (nt 591-640 in SEQ ID NO: 1) and 20 nt specific for the plasmid pKan-SacB (designated as "pr-f" in Fig. 2). The primer crp-10r contained 51 nt from the crp promoter region (nt 714-764 in SEQ ID NO: 1, in reverse complementary form) and 21 nt specific for the plasmid pKan-SacB (designated as "pr-r" in Fig. 2). 3. E. coli W3110 x pKD46 was transformed with the 3.2 kb PCR product specific for the crp promoter region, and kanamycin-resistant clones were isolated on LBkan plates (10 g / L tryptone, 5 g / L yeast extract, 5 g / L NaCl, 1.5% agar, 15 mg / L kanamycin). 4. Kanamycin-resistant clones were inoculated onto LBSC plates (10 g / L tryptone, 5 g / L yeast extract, 7% sucrose, 1.5% agar, and 15 mg / L kanamycin). Clones with the integrated sacB gene produced toxic levan from sucrose, leading to growth inhibition. 5.From cells grown from kanamycin-resistant and sucrose-sensitive clones in LBkan medium (10 g / L tryptone,.
[0162] Genomic DNA was isolated using a DNA isolation kit (Qiagen) from a 5 g / L yeast extract (5 g / L NaCl, 15 mg / L kanamycin). 6. Genomic DNA was used in a PCR reaction (Phusion™ High-Fidelity DNA polymerase, Thermo Scientific™) with the primers crp-7f (SEQ ID NO: 5) and crp-8r (SEQ ID NO: 6) to detect the integration of the Kan-sacB cassette.
[0163] E. coli W3110 wild-type DNA yielded a 1696 nt DNA fragment (corresponding to the sequence in SEQ ID NO: 1) in the PCR reaction, as expected for the intact gene structure consisting of yhfA-cds, the crp promoter, and crp-cds. Kanamycin-resistant clones, however, yielded a DNA fragment of approximately 4800 nt in the PCR reaction, as expected if the 3.2 kb PCR product had been integrated into the crp promoter at the sites defined by primers crp-9f and crp-10r. By integrating the 3.2 kb Kan-sacB cassette at the sites defined by primers crp-9f and crp-10r, confirmed by DNA sequencing of the 4800 nt PCR product, 74 nucleotides were removed from the crp promoter (SEQ ID NO: 1, nt 641–nt 713). 7. A clone with an integrated Kan-sacB cassette was selected and designated W3110-crp::kan-sacB x pKD46. 8. The temperature-sensitive plasmid pKD46 was removed by incubation at 42°C.Clones lacking the pKD46 plasmid were ampicillin-sensitive and could no longer grow on LBamp plates. An ampicillin-sensitive clone was selected and designated W3110-crp::kan-sacB. Example 2: Generation of W3110 strains with differently truncated crp promoters.
[0164] The following W3110 strains with a truncated crp promoter were produced:
[0165] W3110-crpP-del: Deletion nt 565 - nt 865 from SEQ ID NO: 1
[0166] W3110-crp-Preg: Deletion nt 565 - nt 713 from SEQ ID NO: 1
[0167] W3110-crp-Preg2: Deletion nt 565 - nt 675 from SEQ ID NO: 1
[0168] W3110-crp-Preg3: Deletion nt 565 - nt 624 from SEQ ID NO: 1
[0169] W3110 strains with a truncated crp promoter were generated by homologous recombination of the kan-sacB cassette of the
[0170] strain W3110-crp::kan-sacB was replaced by a DNA fragment containing the modified promoter sequence. DNA fragments with the modified promoter sequences were generated in a conventional manner by fusion PCR (so-called OE-PCR, abbreviated for "Overlap Extension PCR") from two PCR products defining the modified promoter. To generate the PCR products described below, "Phusion™ High-Fidelity" DNA polymerase (Thermo Scientific™) was used according to the manufacturer's instructions.
[0171] The following primers were used: crp-13f (SEQ ID NO: 7): corresponds to nt 160-180 in SEQ ID NO: 1. crp-14r (SEQ ID NO: 8): corresponds to nt 545-564 in SEQ ID NO: 1; in reverse complementary form. crp-17f (SEQ ID NO: 9): corresponds to nt 537-565 (nt 1 to 29 in crp-17f) and nt 866-885 (nt 30 to 49 in crp-17f) in SEQ ID NO: 1. crp-12r (SEQ ID NO: 10): corresponds to nt 1478-1498 in SEQ ID NO: 1; in reverse complementary form. crp-18f (SEQ ID NO: 11): corresponds to nt 537 - 564 (nt 1 to 28 in crp-18f) and nt 714 - 734 (nt 29 to 49 in crp-18f) in SEQ ID NO: 1. crp-19f (SEQ ID NO: 12): corresponds to nt 537 - 564 (nt 1 to 28 in crp-19f) and nt 676 - 700 (nt 29 to 53 in crp-19f) in SEQ ID NO: 1. crp-20f (SEQ ID NO: 13): corresponds to nt 537 - 564 (nt 1 to 28 in crp-20f) and nt 625 - 644 (nt 29 to 48 in crp-20f) in SEQ ID NO: 1.
[0172] The following PCR products were produced:
[0173] PCR 1: A 0.4 kb PCR product was produced by PCR with genomic DNA from E. coli W3110 and the primers crp-13f and crp-14r.
[0174] PCR 2: A 0.65 kb PCR product was produced by PCR with genomic DNA from E. coli W3110 and the primers crp-17f and crp-12r.
[0175] PCR 3: A 0.8 kb PCR product was produced by PCR with genomic DNA from E. coli W3110 and the primers crp-18f and crp-12r.
[0176] PCR 4: A 0.8 kb PCR product was produced by PCR with genomic DNA from E. coli W3110 and the primers crp-19f and crp-12r.
[0177] PCR 5: A 0.8 kb PCR product was produced by PCR with genomic DNA from E. coli W3110 and the primers crp-20f and crp-12r.
[0178] The following fusion PCR products were generated by OE-PCR (Overlap Extension PCR), as described, for example, in Hilgarth and Lanigan, MethodsX (2020), 7: 100759:
[0179] PCR 6: 1 kb fusion PCR product for the production of the E. coli W3110-crpP-del strain by OE-PCR of PCR 1 and PCR 2 and primers crp-13f and crp-12r. PCR 7: 1.2 kb fusion PCR product for the production of the strain
[0180] E. coli W3110-crp-Preg by OE-PCR of PCR 1 and PCR 3 and primers crp-13f and crp-12r.
[0181] PCR 8: 1.2 kb fusion PCR product for the production of the strain
[0182] E. coli W3110-crp-Preg2 by OE-PCR of PCR 1 and PCR 4 and primers crp-13f and crp-12r.
[0183] PCR 9: 1.2 kb fusion PCR product for the production of E. coli W3110-crp-Preg3 strain by OE-PCR of PCR 1 and PCR 5 and primers crp-13f and crp-12r.
[0184] Transformation of E. coli W3110-crp::kan-sacB x pKD46: The fusion PCR products PCR 6, PCR 7, PCR 8, and PCR 9 were each transformed into E. coli W3110-crp::kan-sacB x pKD46, and clones were selected on LBS plates (10 g / L tryptone, 5 g / L yeast extract, 7% sucrose, 1.5% agar) without kanamycin. Only clones that no longer contained an active sacB gene could grow on LBS plates. These clones were inoculated onto LBkan plates to select clones that also no longer contained an active Kan gene and whose growth was inhibited in the presence of kanamycin. One clone was selected in each case, and the temperature-sensitive plasmid pKD46 was removed by incubation at 42°C. Clones lacking the pKD46 plasmid were ampicillin-sensitive and could no longer grow on LBamp plates. The respective clones were designated E. coli W3110-crpP-del, E. coli W3110-crp-Preg, E. coli W3110-crp-Preg2, and E. coli W3110-crp-Preg3, respectively.
[0185] PCR analysis of the transformants:
[0186] Clones with positive growth in the presence of sucrose and negative growth in the presence of kanamycin were selected, and genomic DNA was isolated from cells grown in LB medium (10 g / L tryptone, 5 g / L yeast extract, 5 g / L NaCl) using a DNA isolation kit (Qiagen). Genomic DNA was used in a PCR reaction ("Phusion™ High-Fidelity" DNA polymerase, Thermo Scientific™) with primers crp-7f and crp-8r to verify that the Kan-sacB cassette had been correctly replaced by the respective fusion PCR product. Clones with a PCR product of the expected size were selected, and the correct incorporation of the modified promoter sequence and the unmodified sequence of the crp-cds were analyzed by DNA sequencing of the PCR products (Eurofins Genomics).
[0187] The PCR products had the following expected sizes:
[0188] strain E. coli W3110-crpP-del: 1397 nt. Deletion nt 565 - nt 865 from SEQ ID NO: 1.
[0189] Strain E. coli W3110-crp-Preg: 1549 nt. Deletion nt 565 - nt 713 from SEQ ID NO: 1.
[0190] Strain E. coli W3110-crp-Preg2: 1587 nt deletion nt 565 - nt 675 from SEQ ID NO: 1.
[0191] Strain E. coli W3110-crp-Preg3: 1637 nt deletion nt 565 - nt 624 from SEQ ID NO: 1.
[0192] Example 3: Production of cysteine production strains
[0193] The cysteine-specific production plasmid pCys (Fig. 3) was used to generate cysteine production strains (strains with deregulated cysteine biosynthesis). pCys is a derivative of the plasmid pACYC184-cysEX-GAPDH-ORF306 disclosed in EP 0885 962 B1.
[0194] The plasmid pACYC184-cysEX-GAPDH-ORF306 contains, in addition to the replication origin and a tetracycline resistance gene (starting vector pACYC184), the cysEX allele, which encodes a serine Q-acetyltransferase with reduced feedback inhibition by cysteine, as well as the efflux gene ydeD (ORF306), whose expression is controlled by the constitutive GAPDH promoter. Furthermore, pCys contains, cloned behind the ydeD (QRF306) efflux gene, the serA317 gene fragment, encoding the N-terminal 317 amino acids of the SerA protein (total length 410 amino acids). The E. coli serA gene is disclosed in the "GenBank" gene database with the gene ID 945258. serA317 is disclosed in Bell et al. 2002 (see above, referred to therein as "NSD:317") and encodes a serine feedback-resistant variant of 3-phosphoglycerate dehydrogenase. The expression of serA317 is controlled by the serA promoter.
[0195] The strains E. coli W3110, E. coli W3110-crp::kan-sacB, E. coli W3110-crpP-del, E. coli W3110-crp-Preg, E. coli W3110-crp-Preg2 and E. coli W3110-crp-Preg3 were each transformed with the plasmid pCys.
[0196] Plasmid-bearing transformants were selected on LBtet agar plates (10 g / L tryptone, 5 g / L yeast extract, 5 g / L NaCl, 1.5% agar, 15 mg / L tetracycline). One clone was selected for each. The strains used in the following examples were given the following names:
[0197] E. coli W3110 x pCys,
[0198] E. coli W3110-crp::kan-sacB x pCys
[0199] E. coli W3110-crpP-del x pCys
[0200] E. coli W3110-crp-Preg x pCys
[0201] E. coli W3110-crp-Preg2 x pCys
[0202] E. coli W3110-crp-Preg3 x pCys
[0203] Example 4: Cultivation in a shake flask
[0204] Pre-culture: As a pre-culture for the cultivation in the shake flask, 3 ml of LBtet medium (10 g / L tryptone, 5 g / L yeast extract, 10 g / L NaCl, 15 mg / L tetracycline) were inoculated with the respective cysteine production strain from Example 3 and incubated at 30°C and 135 rpm for 16 h in a shaker (Infors) and the OD 600 / ml (optical density of the culture / ml culture, measured at 600 nm). Main culture: Subsequently, 300 ml Erlenmeyer flasks (with baffle) were inoculated with 30 ml SML medium containing 15 g / L glucose, 5 mg / L vitamin B1, 2 g / L sodium thiosulfate, and 15 mg / L tetracycline, with a volume of the preculture such that an OD 600 / ml of 0.05.
[0205] Composition of SMl medium: 12 g / L K2HPO4, 3 g / L KH2PO4, 5 g / L (NH4)2SO4, 0.3 g / L MgSO4x 7 H2O, 0.015 g / L CaCl2x 2 H2O, 0.002 g / L FeSO4x 7 H2O, 1 g / L Na3Citrate x 2 H2O, 0.1 g / L NaCl;
[0206] 1 ml / L trace element solution.
[0207] Composition of the trace element solution: 0.15 g / L Na2MoO4x 2 H2O, 2.5 g / L H3BO3, 0.7 g / L CoCl2x 6 H2O, 0.25 g / L CuSO4x 5 H2O, 1.6 g / L MnCl2x 4 H2O, 0.3 g / L ZnSO4x 7 H2O.
[0208] To isolate RNA for RT-PCR experiments, the 30 ml batches were incubated at 30°C and 140 rpm to an OD 600 / ml of 0.5 / ml (4 - 5 h incubation time).
[0209] To determine cysteine production, the 30 ml batches were incubated for 24 h at 30°C and 140 rpm.
[0210] For the comparative analysis of cysteine production of a WT strain with non-deregulated cysteine biosynthesis in Example 6, the strain E. coli W3110 without plasmid pCys was grown in the same way, but in the culture of this strain with non-deregulated cysteine biosynthesis, all media did not contain tetracycline.
[0211] Example 5: Analysis of crp expression by RT-PCR
[0212] 1) Isolation of RNA: 0.5 ml main culture with an OD 600 To stabilize the RNA, 1 ml of RNA-Protect® ("Bacteria Reagent", Qiagen) was added to the RNA concentration of 0.5 / ml from Example 4. RNA was isolated from the samples using the RNeasy RNA isolation kit (RNeasy Mini Kit, Qiagen) according to the manufacturer's instructions. Depending on the strain, 8 to 10 pg of RNA were isolated from 0.5 ml of main culture. The RNA concentration was determined using the Qubit 3.0 Fluorometer from Thermo Fisher Scientific using the "Qubit™ RNA BR Assay Kit" according to the manufacturer's instructions.
[0213] 2) Preparation of complementary DNA (cDNA): 1.5 pg of isolated RNA was converted to cDNA by reverse transcription using the QuantiNova™ Reverse Transcription Kit (Qiagen). The cDNA concentration was determined using a Qubit 3.0 Fluorometer from Thermo Fisher Scientific using the "Qubit™ dsDNA HS Assay Kit" according to the manufacturer's instructions. The cDNA yield from 1.5 pg of RNA was 350–390 ng.
[0214] 3) RT-PCR: A RotorGene Q 2plex RT-PCR system from Qiagen was used, operated with the RotorGene Q control and analysis software from the same manufacturer. The QuantiNova™Sybr® Green PCR Kit for Real-Time PCR (Qiagen) was also used.
[0215] The expression of the crp gene and the cysG gene were analyzed as a reference gene. The reference gene cysG served as an internal standard with little variation in expression (Zhou et al. 2011 (see above)), against which the expression of the crp gene was compared.
[0216] The following primers were used: crp gene: primers crp-lf (SEQ ID NO: 14) and crp-2r (SEQ ID NO: 15). cysG gene: primers cysg-lf (SEQ ID NO: 16) and cysg-2r (SEQ ID NO: 17).
[0217] cDNA from the shake flask culture of the six strains from Example 4 transformed with the plasmid pCys was analyzed, with the crp expression in strain W3110 x pCys serving as a reference point for the evaluation of the relative expression of the crp gene (comparison strain; crp expression from the wild-type promoter), against which the crp expression of the other strains was compared. For statistical security, each RT-PCR reaction was carried out four identical times in replicates (quadruple determination). For the cDNA of the six strains, the RT-PCR reactions for both the cysG reference gene and the crp gene to be determined were carried out simultaneously in a single run. This corresponded to a total of 48 RT-PCR reactions for a quadruplicate determination of the expression of two genes per strain.
[0218] RT-PCR approaches: An RT-PCR approach (final volume 20 μl) for analyzing the expression of the crp gene was composed of 10 μl H2O, containing 20 ng cDNA and 14 pmol each of the crp-specific primers crp-lf and crp-2r as well as 10 μl QuantiNova™Sybr® Green Mastermix for Real-Time PCR (Qiagen), containing the DNA polymerase and the fluorescent dye Sybr® Green for detecting newly formed DNA. An RT-PCR mixture (final volume 20 μl) for the analysis of the expression of the cysG gene was composed of 10 μl H2O, containing 20 ng cDNA and 14 pmol each of the cysG-specific primers cysg-lf and cysg-2r as well as 10 μl QuantiNova™Sybr® Green Mastermix for Real-Time PCR (Qiagen), containing the DNA polymerase and the fluorescent dye Sybr® Green for the detection of newly formed DNA.
[0219] After an initial incubation of 2 minutes at 95°C, the RT-PCR program consisted of 40 cycles of 5 cycles at 95°C and 10 cycles at 60°C. The fluorescence signal evoked by the binding of Sybr® Green to newly formed double-stranded DNA was recorded by a detector on the RT-PCR instrument, and its temporal progression was analyzed by the analysis software.
[0220] 4) RT-PCR analysis: The analysis software determined the CRP expression of a strain relative to the CRP expression of the reference strain W3110 x pCys. The analysis was based on the so-called 2 -ΔΔCT -method, the mathematical derivation of which was described by Livak and Schmittgen 2001 (see above). For the reference strain, this analysis resulted in a 2 -ΔΔCT -value of 1. Values > 1 therefore mean increased crp expression, values < 1 correspondingly mean reduced crp expression.
[0221] From the temporal course of the fluorescence signal, the evaluation software determined the mean value of the so-called CT value (CT "Cycle Threshold") for each quadruplicate sample and, in a first step, the difference ACT between the CT values of the crp gene and the cysG reference gene was calculated for each strain as ACT = CT crp - CT cysG In a second step, the difference AACT between the ACT value of a strain to be analyzed and the ACT value of the reference strain W3110 x pCys was calculated as AACT = ACT - ACT W3110 x pcys • In a third step, the AACT value was converted to 2 -ΔΔCT which represented a measure of the relative expression of the crp gene of a strain compared to the expression of the crp gene in the reference strain W3110 x pCys (Wt crp promoter). Table 1 summarizes the relative crp expression of the strains examined compared to the expression of the reference strain W3110 x pCys (expression normalized to the value 1). **) ΔΔCT: ΔCT - ΔCT(reference strain W3110 x pCys)
[0222] Example 6: Determination of cysteine production from shake flask culture supernatants
[0223] Samples were taken from the main cultures from Example 4 after 24 h of cultivation and the cell density OD 600 / ml and the total cysteine content in the culture supernatant were determined, using the colorimetric test by Gaitonde (1967) (see above) for the quantitative determination of cysteine. 20 μl of culture supernatant were added to 2 ml of the test mixture. It should be noted that, under the strongly acidic reaction conditions, this test does not distinguish between cysteine and the condensation product of cysteine and pyruvate, 2-methylthiazolidine-2,4-dicarboxylic acid (thiazolidine), described in EP 0885 962 B1. L-cystine, which is formed by the oxidation of two cysteine molecules according to equation (2), is also detected as cysteine in the test by reduction with dithiothreitol in dilute solution at pH 8.0.
[0224] Tab. 2 contains the cell density (OD 600 / ml) and the cysteine content (cysteine mg / ml) of the main cultures, as well as the cell density-related specific cysteine production (cysteine mg / OD) and the specific cysteine production (cysteine % of W3110 x pCys) in percent relative to the reference strain W3110 x pCys (=100%).
[0225] Tab. 2: Cysteine production in shake flasks of W3110 strains with modified crp promoter
[0226] Example 7: Cysteine product!on in the fermenter
[0227] E. coli W3110 x pCys, W3110-crp::kan-sacB x pCys, W3110-crp-Preg2 x pCys, and W3110-crp-Preg3 x pCys were compared in a production-scale fed-batch fermentation. The E. coli W3110-crpP-del x pCys and W3110-crp-Preg x pCys strains with the lowest crp expression (Table 1) were not further investigated due to poor growth in the fermenter.
[0228] Preculture 1: 20 ml of LBtet medium were inoculated with the respective strain in a 100 ml Erlenmeyer flask and incubated for 7 h on a shaker (150 rpm, 30°C).
[0229] Pre-culture 2:
[0230] Subsequently, the respective precultures 1 were completely transferred into 100 ml of SMl medium supplemented with 5 g / L glucose, 5 mg / L vitamin B1 and 15 mg / L tetracycline (for the composition of SMl medium, see Example 4).
[0231] The cultures were shaken in Erlenmeyer flasks (1 L volume) at 30°C for 17 h at 150 rpm (Infors chest shaker). After this incubation, the cell density OD 600 / ml between 3 and 5.
[0232] Main crop:
[0233] Fermentation was carried out in a fermenter of the type "DASGIP® Parallel Bioreactor Systems for Microbiology" from Eppendorf. Culture vessels with a total volume of 1.81 were used. The fermentation medium (900 ml) contained 15 g / L glucose, 10 g / L tryptone (Difco), 5 g / L yeast extract (Difco), 5 g / L (NH4)2SO4, 1.5 g / L KH2PO4, 0.5 g / L NaCl, 0.3 g / L MgSO4x 7 H2O, 0.015 g / L CaCl2x 2 H2O, 0.075 g / L FeSO4x 7 H2O, 1 g / L Na3Citrate x 2 H2O and 1 ml trace element solution (see Example 6), 0.005 g / L vitamin Bl and 15 mg / L tetracycline.
[0234] The pH in the fermenter was initially adjusted to 7.0 by pumping in a 25% NH4OH solution. During fermentation, the pH was maintained at 7.0 by automatic correction with 25% NH4OH.
[0235] For inoculation, 100 ml of preculture 2 was pumped into the fermenter vessel. The initial volume was thus approximately 1 L. The cultures were initially stirred at 400 rpm and aerated with compressed air sterilized through a sterile filter at an aeration rate of 2 vvm (vvm: compressed air input into the fermentation mixture expressed in liters of compressed air per liter of fermentation volume per minute). Under these initial conditions, the oxygen probe was calibrated to 100% saturation before inoculation.
[0236] The target value for O2 saturation during fermentation was set to 30%. Once the O2 saturation dropped below the target value, a regulation cascade was initiated to bring the O2 saturation back to the target value. First, the gas supply was continuously increased (to a maximum of 5 vvm) and then the stirring speed was continuously increased (to a maximum of 1,500 rpm).
[0237] Fermentation was carried out at a temperature of 30°C. After 2 h of fermentation, a sulfur source in the form of a sterile 60% (w / v) stock solution of sodium thiosulfate x 5 H2O was added at a rate of 1.5 ml per hour.
[0238] Once the glucose content in the fermenter had dropped from an initial 15 g / L to approximately 2 g / L, a 56% (w / w) glucose solution was continuously added. The feed rate was adjusted so that the glucose concentration in the fermenter no longer exceeded 2 g / L. Glucose was determined using a glucose analyzer from YSI (Yellow Springs, Ohio, USA).
[0239] The fermentation lasted 48 hours. Samples were then taken from the fermentation batch, and the content of L-cysteine and its derivatives in the culture supernatant (primarily L-cysteine and thiazolidine) and in the precipitate (L-cystine) was determined separately. For this purpose, the colorimetric test of Gaitonde 1967 (see above) was used.
[0240] The L-cystine present in the precipitate had to be dissolved in 8% (v / v) hydrochloric acid before it could be quantified in the same way. Finally, the total amount of cysteine was determined as the sum of cysteine in the pellet and the supernatant. As summarized in Table 3, the cell density OD 600 / ml of the strains tested. However, cysteine volume production (in g / L) was higher in W3110-crp::kan-sacB x pCys, W3110-crp-Preg2 x pCys, and W3110-crp-Preg3 x pCys than in the control strain W3110 x pCys with an unaltered crp promoter.
Claims
Patent claims 1. A strain of microorganisms with a deregulated cysteine biosynthesis pathway, which is thereby suitable for the fermentative production of at least one substance selected from L-cysteine, L-cystine and thiazolidine, characterized in that the relative expression of the crp gene is reduced by mutation of the crp promoter sequence compared to the expression of the crp gene with wild-type promoter sequence.
2. Microorganism strain according to claim 1, characterized in that the amino acid sequence of the Crp protein is not mutated.
3. Microorganism strain according to one or more of claims 1 or 2, characterized in that the mutation in the crp promoter sequence comprises at least one deletion or insertion.
4. Microorganism strain according to one or more of claims 1 to 3, characterized in that at least nt 565-624 is deleted from the crp-promoter sequence specified in SEQ ID NO: 1 nt 565-865.
5. Microorganism strain according to one or more of claims 1 to 4, characterized in that the crp promoter sequence is completely deleted.
6. Microorganism strain according to one or more of claims 1 to 5, characterized in that the microorganism strain is a strain from the family Enterobacteriaceae or Corynebacteriaceae.
7. Microorganism strain according to one or more of claims 1 to 6, characterized in that the The microorganism strain selected is from the group consisting of Escherichia coli, Pantoea anana tis and Corynebacterium glutamicum.
8. Microorganism strain according to one or more of claims 1 to 7, characterized in that the microorganism strain is a strain of the species Escherichia coli.
9. Microorganism strain according to one or more of claims 1 to 8, characterized in that the expressed Crp protein is SEQ ID NO : 2 .
10. A method for producing at least one compound selected from L-cysteine, L-cystine and thiazolidine, characterized in that a strain of microorganism according to one of claims 1 to 9 is used.
11. Method according to claim 10, characterized in that the L-cysteine, L-cystine or thiazolidine formed is isolated.
12. Method according to claim 11, characterized in that the crp expression of the microorganism strain with modified crp promoter sequence is reduced by at least 9% compared to a corresponding microorganism strain with Wt-crp promoter sequence and the yield of a substance selected from L-cysteine, L-cystine and thiazolidine in g / l is increased by at least 10% (w / v) when using the microorganism strain.
13. Method according to one or more of claims 10 to 12 , characterized in that the process is a fermentative process and the fermentation volume is at least 1 L .
